How have you incorporated mirvetuximab into the treatment of platinum-resistant ovarian cancer?

This question is going to be increasingly important in the current landscape of ovarian cancer management.

I have prioritized early ordering of biomarker testing so that I have the test profiles available at recurrence, particularly in the platinum-resistant standpoint.

I find that toxicity, patient ...

Related to Q1, this has been on my radar for a couple of years as I was the PI for SORAYA, so I had access to the agent before FDA accelerated approval – now with regular approval. Since the MIRASOL trial demonstrated benefit over standard single agent chemotherapy, it’s preferred if eligible. I am ...